Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX – Get Free Report) gapped down prior to trading on Thursday. The stock had previously closed at $35.24, but opened at $33.45. Nanobiotix shares last traded at $32.6720, with a volume of 24,122 shares traded.
Analyst Upgrades and Downgrades
A number of equities research analysts have recently issued reports on the company. Guggenheim began coverage on Nanobiotix in a research report on Tuesday, September 15th. They set a “buy” rating and a $64.00 target price on the stock. Leerink Partners increased their price target on Nanobiotix from $37.00 to $46.00 and gave the company an “outperform” rating in a research report on Thursday, June 4th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Nanobiotix in a research note on Friday, July 17th. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $46.67.
View Our Latest Stock Analysis on NBTX
Nanobiotix Price Performance
Nanobiotix (NASDAQ:NBTX – Get Free Report) last posted its quarterly earnings data on Tuesday, September 29th. The company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.48) by $0.08. The firm had revenue of $3.17 million for the quarter, compared to analysts’ expectations of $1.73 million. As a group, research analysts forecast that Nanobiotix S.A. – Sponsored ADR will post -0.16 earnings per share for the current year.
Nanobiotix Company Profile
Nanobiotix is a clinical-stage biotechnology company focused on developing nanomedicine-based therapies for cancer. The company’s technology is designed to improve the effectiveness of radiotherapy by using nanoparticles that interact with radiation inside tumors, with the goal of enhancing tumor-cell destruction while limiting damage to surrounding healthy tissue.
Its lead product candidate, NBTXR3, is an investigational radioenhancer consisting of functionalized hafnium oxide nanoparticles.
See Also
- Five stocks we like better than Nanobiotix
- Costco Ends Its Fiscal Year on a High Note, Eyes Big Expansion
- Cracker Barrel Stock Is Rallying Again, But the Turnaround Still Has a Traffic Problem
- Oracle’s Force Majeure Notice Exposes a Bigger Problem for the AI Build-Out
- Oil May Be Stronger Than It Looks—And Diamondback Is on Sale
Receive News & Ratings for Nanobiotix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nanobiotix and related companies with MarketBeat.com's FREE daily email newsletter.
